Lung (includes NSCLC, SCLC, Mesothelioma)

Roche Cancer Immunotherapy Tecentriq Wins EU Approval

(Reuters) Sept 23, 2017 - Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said.

read article

Adding Radiation To Chemotherapy May Dramatically Improve Survival For Advanced-Stage NSCLC Patients

(ASTRO 59th Annual Meeting) Sept 24, 2017 - Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial.

read press release

Long-term Survival Rates More Than Double Previous Estimates For Locally Advanced Lung Cancer

(ASTRO 59th Annual Meeting) Sept 24, 2017 - Phase III trial demonstrates 32 percent overall survival rate at five years following standard-dose treatment for stage III NSCLC; trial also finds no additional benefit from cetuximab.

read press release

EU Green Light For Roche’s Tecentriq

(PharmaTimes [UK]) Sept 25, 2017 - Roche has received European Commission approval for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab) to treat specific lung and bladder cancers.

read article

Results of NRG Oncology SBRT Comparison Trial for Lung Cancer Patients Consistent after Long-term Follow-up

(NRG Oncology) Sept 24, 2017 - Long-term follow-up of NRG Oncology trial RTOG 0915 displayed no excess in late-appearing toxicity and similar primary tumor control in both original study arms.

read press release

Biomarker Blood Test Predicts Survival Following Localized Lung Cancer Treatment

(ASTRO 59th Annual Meeting) Sept 24, 2017 - A new study demonstrates that a blood test to detect cancer may predict treatment outcomes for patients with localized non-small cell lung cancer (NSCLC) and afford physicians additional lead time to personalize treatment for recurrent disease.

read press release

AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors

(StreetInsider) Sept 22, 2017 - AbbVie and Bristol-Myers Squibb Company today announced a clinical trial collaboration to evaluate the combination of AbbVie’s investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

read article

New First Line Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer

(Yahoo! Finance) Sept 20, 2017 - Merck, known as MSD outside Canada and the United States , announced today that KEYTRUDA® (pembrolizumab) as monotherapy is now indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have high PD-L1 expression, with no EGFR or ALK genomic tumour aberrations and no prior systemic chemotherapy treatment.

read article

UK Backs Opdivo For Lung Cancer After Bristol-Myers Cuts Price

(Reuters) Sept 20, 2017 - Bristol-Myers Squibb’s immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain’s healthcare cost watchdog NICE after the drugmaker agreed a discounted price.

read article

Expected Burden of Lung Cancer High for People Living With HIV

(Modern Clinician/HealthDay News) Sept 18, 2017 - For people living with HIV (PLWH), the expected burden of lung cancer is high, if smoking habits do not change, according to a study published online Sept. 18 in JAMA Internal Medicine.

read article

FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

(MarketWatch) Sept 14, 2017 - Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin [®] (bevacizumab).

read article

Amgen Is Taking On a $3 Billion Cancer Drug. But Will It Cut Costs for Patients?

(Fortune) Sept 15, 2017 - The Food and Drug Administration (FDA) continued its potentially record-breaking pace of new drug approvals Thursday, green lighting the first-ever "biosimilar" copycat of a cancer drug.

read article

Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer

(Business Insider) Sept 14, 2017 - Mirati Therapeutics, Inc. announced that positive preliminary data from two ongoing clinical trials of sitravatinib in non-small cell lung cancer (NSCLC) will be presented Friday, September 15th, 2017 at the IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology.

read article

FDA Approves First Biosimilar For The Treatment Of Cancer

(FDA.gov) Sept 14, 2017 - The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

read press release

Researchers Develop New Strategy to Target KRAS Mutant Cancer

(UC San Diego Health) Sept 13, 2017 - Although KRAS is one of the major oncogenes associated with aggressive cancers, drugs designed to block KRAS function have not been able to halt cancer progression in a clinical setting. Until now, KRAS has remained infamously "undruggable."

read press release

Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab)

(The Business Journals) Sept 12, 2017 - Nektar Therapeutics today announced that it has begun dosing in the PROPEL clinical study which will evaluate the efficacy and safety of NKTR-214, the company's lead immuno-oncology candidate in combination with approved checkpoint inhibitors, TECENTRIQ® (atezolizumab) and KEYTRUDA® (pembrolizumab).

read article

Best Poster at ESMO 2017 Shows Positive Trials Twice as Likely to be Reported in Lay Press

(ESMO 2017 Congress) Sept 12, 2017 - Randomised controlled trials with positive results are twice as likely to be reported by the lay press as those with negative trials, according to results from the Best Poster in Public Health and Health Economics at the ESMO 2017 Congress in Madrid.

read press release

Best of ESMO 2017 Congress

(ESMO 2017 Congress) Sept 12, 2017 - ESMO 2017 was a truly global event with nearly 24,000 participants from 131 countries. The ten countries with the most delegates were the USA, France, Spain, UK, Germany, Italy, Switzerland, China, Japan, and Russia.

read press release

‘Epigenetic’ Changes From Cigarette Smoke May be First Step in Lung Cancer Development

(Johns Hopkins Medicine) Sept 11, 2017 - Scientists at the Johns Hopkins Kimmel Cancer Center say they have preliminary evidence in laboratory-grown, human airway cells that a condensed form of cigarette smoke triggers so-called "epigenetic" changes in the cells consistent with the earliest steps toward lung cancer development.

read press release

ESMO 2017 Round Up: BMS and AZ Bounce Back

(pharmaphorum [UK]) Sept 12, 2017 - Europe’s biggest cancer congress ESMO wraps up today, having delivered its fair share of major studies and talking points in cancer treatment over five days.

read article
Next Page